10x Genomics, Inc.
corporate_fare Company Profile
10x Genomics, Inc. (NASDAQ:TXG) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 9 items for TXG at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-09-29, rated 8/10. Across its 9 most recent items scored 7 or higher, the top rating is 8/10, with 5 rated 8 or above. Recent SEC coverage for TXG spans 10-Q, 8-K, 10-K.
Recent high-impact activity:
- 10x Genomics Ships First Atera Instruments as Demand Tops 2026 Target
- 10x Genomics Q2 Revenue Drops 13% as Patent Settlement Windfall Fades; New IP Suits Filed
- 10x Genomics Acquires Proteintech Genomics Division
- 10x Genomics Reports Sharply Reduced Q1 Net Loss, Improved Margins, and Key Legal Win
- 10x Genomics Q1 Revenue Beats Estimates, Net Loss Narrows on Cost Cuts
Financial Snapshot
Short Interest & Short Volume
7.09 days to coverFINRA reported short interest of 16,692,300 shares in TXG as of the September 15, 2026 settlement, a 3.3% increase from the prior period — about 7.1 days to cover at its recent average daily volume. On October 2, 2026, 46.8% of TXG volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.